Iuliia Levina

Ms. Iuliia Levina

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Life
Verified
Journal Article
Open access
PDF file
НТНаталья Трушенко
Наталья Трушенко
OSOlga Alexandrovna Suvorova
Olga Alexandrovna Suvorova
EPEkaterina S. Pershina
Ekaterina S. Pershina
GNGalina Nekludova
Galina Nekludova
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
SASergey Avdeev
Sergey Avdeev
Hypersensitivity pneumonitis (HP) is an interstitial lung disease (ILD) resulting from an immune-mediated response in susceptible and sensitized individuals to a large variety of inhaled antigens. Chronic HP with a fibrotic phenotype is characterized by disease progression and a dismal prognosis. The aim of this study was to identify predictors of progression and mortality in patients with chronic HP in real clinical practice. Materials and methods: This retrospective, multicenter, observational study used data from a registry of 1355 patients with fibrosing ILDs. The study included 292 patients diagnosed with chronic HP based on the conclusion of a multidisciplinary discussion (MDD). Results: The patients were divided into groups with progressive (92 (30.3%) patients) and nonprogressive pulmonary fibrosis (200 (69.7%) patients). The most significant predictors of adverse outcomes were a DLco < 50% predicted, an SpO2 at the end of a six-minute walk test (6-MWT) < 85%, and a GAP score ≥ 4 points. Conclusion: Pulmonary fibrosis and a progressive fibrotic phenotype are common in patients with chronic HP. Early detection of the predictors of an adverse prognosis of chronic HP is necessary for the timely initiation of antifibrotic therapy.

29 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
НТНаталья Трушенко
Наталья Трушенко
OSOlga Alexandrovna Suvorova
Olga Alexandrovna Suvorova
ASAnna Shmidt
Anna Shmidt
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
ILIuliia Levina
Iuliia Levina
SASergey Avdeev
Sergey Avdeev
Background: Chronic cough is a common symptom in patients with interstitial lung diseases (ILDs), which significantly affects health-related quality of life (HRQoL). The prevalence of chronic cough varies from 30% to almost 90% in different ILDs, with the highest rate in patients with idiopathic pulmonary fibrosis. However, the pathophysiology of cough in ILDs remains poorly understood, with multiple proposed mechanisms contributing to its development. This knowledge gap complicates both clinical assessment and treatment, as current therapeutic strategies target general cough mechanisms rather than ILD-specific pathways. This review synthesizes existing data to clarify distinct cough mechanisms across ILD subtypes and identify opportunities for more targeted therapeutic strategies in this challenging patient population. Moreover, cough can be a clinical marker of disease severity and a predictor of ILD progression and transplant-free survival. Effective cough-specific therapeutic options that consider potential mechanisms, comorbidities, and individual effects on HRQoL are needed for cough associated with ILD. Therefore, the aim of this review was to analyze the prevalence, the impact on HRQoL, the pathophysiology, and the management of chronic cough in ILDs. Methods: We performed a comprehensive search in PubMed, MEDLINE, Embase, and the Cochrane Library. This review included randomized clinical trials, observational studies, systematic reviews, and meta-analyses in adults with chronic cough comparing ILD types. The following were excluded: commentaries, letters, case reports and case series, conference abstracts, and studies and publications lacking cough-specific outcomes. Results: Several approaches to reduce cough frequency and severity were described: antifibrotic agents, neuromodulators, opiates, inhaled local anesthetics, oxygen, speech therapy, and anti-reflux therapy. Some therapeutic approaches, such as oral corticosteroids and thalidomide, can cause significant side effects. Novel agents, such as P2X3 receptor antagonists, which are in phase III trials (COUGH-1/2), show promising results for refractory cough and may benefit ILD-related cough. Conclusions: Thus, a comprehensive assessment of cough is required for effective cough treatment in patients with ILDs considering possible mechanisms and individual impact on QoL.

1 July 2025 in Tuberculosis and Respiratory Diseases
Verified
Journal Article
Open access
PDF file
НТНаталья Трушенко
Наталья Трушенко
BLBaina Baatrovan Lavginova
Baina Baatrovan Lavginova
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
NONatalia E. Obukhova
Natalia E. Obukhova
ILIuliia Levina
Iuliia Levina
SASergey Avdeev
Sergey Avdeev
Background: Incorrect inhalation technique is a primary cause of therapeutic failure in chronic obstructive pulmonary disease (COPD), leading to increased exacerbation frequency. Identifying predictors of suboptimal peak inspiratory flow (sPIF) can significantly enhance treatment efficacy in COPD patients. The objective of this study was to identify the prevalence and predictors of sPIF in hospitalized patients with acute exacerbation of COPD in a clinical setting.Methods: This study enrolled 72 patients hospitalized for acute COPD exacerbation. It analyzed demographic, clinical, and lung function parameters. Peak inspiratory flow (PIF) was measured using an In-Check DIAL G16 (Alliance Tech Medical) across different resistance levels of the patients’ inhalation devices, both before and after instruction in inhalation technique, and at various resistance settings (R2 and R5) upon admission and discharge.Results: Initially, 52.7% of patients exhibited sPIF, which decreased to 19.4% following inhalation technique education (p70 years, forced vital capacity <73% predicted (pred.), forced expiratory volume in 1 second (FEV1) 194% pred., RV/total lung capacity >70%, and diffusing capacity for carbon monoxide <36% pred. as independent predictors of sPIF. The most significant predictors were age (odds ratio [OR], 0.89) and FEV1 (OR 0.59).Conclusion: Selecting a suitable dry powder inhaler for maintenance therapy in patients with acute exacerbation of COPD requires consideration of the patient's ability to achieve optimal PIF, with special attention to age and severity of functional impairment.

21 June 2025 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
OSOlga Alexandrovna Suvorova
Olga Alexandrovna Suvorova
НТНаталья Трушенко
Наталья Трушенко
BLBaina Baatrovan Lavginova
Baina Baatrovan Lavginova
ILIuliia Levina
Iuliia Levina
ZMZamira M. Merzhoeva
Zamira M. Merzhoeva
SASergey Avdeev
Sergey Avdeev
Background. Idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) are interstitial lung diseases with similar symptoms: dyspnea and cough, which determine disease severity and serve as prognostic markers. Aim. To compare clinical and functional characteristics and their dynamics in patients with IPF and different HP phenotypes, and to assess the relationship between symptoms and objective test results. Materials and methods. A longitudinal observational study included 153 patients (48 with IPF, 105 with HP, including 72 fibrotic HP [fHP], of whom 32 had a UIP pattern). Demographic, anamnestic, and functional parameters (spirometry, body plethysmography, DLco) were analyzed. Dyspnea (mMRC scale), cough (VAS and LCQ questionnaire), 6MWT results, HRCT changes, and echocardiographic signs of right heart dysfunction were assessed at baseline and after 12 months. Statistical analysis included nonparametric tests, Spearman correlation, and multiple linear regression to evaluate the impact of parameters on dyspnea and cough. Results. Patients with fHP and fHP+UIP did not significantly differ from IPF patients in dyspnea severity (mMRC), cough intensity (VAS), or functional parameters. Mortality and disease progression were comparable between IPF, fHP, and fHP+UIP groups. Dyspnea severity correlated with GAP scores, 6MWT distance, SpO2 at baseline and end of 6MWT, presence of fibrosis on HRCT, functional parameters (DLco, CPI, etc.), and Charlson Comorbidity Index. Regression analysis showed that end-exercise SpO2 and pulmonary fibrosis had the greatest impact on dyspnea. Cough correlated with fibrosis, dyspnea (mMRC), and functional parameters (FVC, FEV1, CPI). FEV1 and pulmonary fibrosis were the most significant predictors of cough severity. Conclusion. Patients with fHP, particularly those with a UIP pattern, have comparable functional impairment and clinical manifestations to IPF patients. Dyspnea and cough are closely associated with exertional desaturation, functional parameters, and pulmonary fibrosis on HRCT, which should be considered when evaluating HP and IPF.

4 May 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
НТНаталья Трушенко
Наталья Трушенко
OSOlga Alexandrovna Suvorova
Olga Alexandrovna Suvorova
EPEkaterina S. Pershina
Ekaterina S. Pershina
GNGalina Nekludova
Galina Nekludova
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
SASergey Avdeev
Sergey Avdeev
Introduction. Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease (ILD). Fibrotic HP is associated with disease progression, impaired lung function, and poor clinical outcomes.Aim. Identify factors that increase the risk of progression of pulmonary fibrosis in patients with HP.Materials and methods. We conducted a retrospective multicenter observational study analyzing data from a fibrosing ILD registry (n = 1355). The study included 292 patients with chronic HP confirmed by multidisciplinary discussion. We evaluated clinical, functional, and laboratory parameters, including 6-minute walk test results and echocardiography findings at baseline and 12-month follow-up. Risk factors for progression were identified through correlation and regression analyses. ROC curve analysis and Kaplan-Meier survival analysis were performed to assess the prognostic significance of various parameters.Results. Among 292 chronic HP patients, fibrosis prevalence was 91.8% with 14.5% mortality. Patients were stratified into progressive fibrosis (n = 92, 30.3%) and non-progressive (n = 200, 69.7%) groups. Regression analysis identified significant predictors of progression: male sex (OR 1.68, 95% CI 1.02–2.76, p = 0,041), smoking (OR 1.1, 95% CI 1.0–1.1, p = 0,002), Charlson Comorbidity Index (OR 1,48, 95% CI 1.03–2.12, p = 0.036), GAP score (OR 1.57, 95% CI 1.1–2.3, p = 0,015), and DLco % predicted (OR 0.93, 95% CI 0.89–0.97, p = 0.001). ROC analysis revealed DLco <50% predicted (p = 0.0001), GAP score ≥4 (p = 0.03), and Charlson Index ≥3 (p = 0.04) as significant progression factors.Conclusion. Patients with fibrotic HP demonstrate high rates of pulmonary fibrosis progression. The main progression predictors include male sex, smoking, higher Charlson Comorbidity Index, DLco < 50% predicted, and GAP score ≥ 4.

1 October 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
OSOlga Alexandrovna Suvorova
Olga Alexandrovna Suvorova
НТНаталья Трушенко
Наталья Трушенко
BLBaina Baatrovan Lavginova
Baina Baatrovan Lavginova
ILIuliia Levina
Iuliia Levina
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
SASergey Avdeev
Sergey Avdeev
Background: Interstitial lung diseases (ILDs) significantly impair health-related quality of life (HRQL). While HRQL in idiopathic pulmonary fibrosis (IPF) is well studied, data on hypersensitivity pneumonitis (HP) remain limited despite comparable clinical impacts. This study evaluates HRQL in patients with IPF and HP using the King’s Brief Interstitial Lung Disease Questionnaire (K-BILD) and EuroQoL 5-Dimension 5-Level Questionnaire (EQ-5D-5L) and examines factors associated with reduced HRQL. Methods: This longitudinal, observational study included 153 patients [48 IPF, 105 HP, including 72 fibrotic HP (fHP), of whom 32 had usual interstitial pneumonia (UIP) pattern (fHP + UIP)]. Demographic, anamnestic and clinical data, HRQL, respiratory function, echocardiography parameters, dyspnea [modified Medical Research Council (mMRC) dyspnea scale], cough [visual analog scale (VAS scale), Leicester Cough Questionnaire (LCQ)], six-minute walk test (6MWT) results, and high-resolution computed tomography (HRCT) changes were assessed at baseline and after 12 months. Statistical analyses included non-parametric tests, correlation, regression, and receiver operator characteristic (ROC)-curve evaluation to identify factors associated with reduced HRQL. Results: IPF patients demonstrated more severe dyspnea and reduced exercise capacity compared to HP, while overall lung function parameters and cough-related measures showed comparable results between the groups. Within the HP cohort, fibrotic forms were associated with greater symptom burden, more advanced physiological impairment, longer diagnostic delay. A statistically significant relationship between the K-BILD and the EQ-5D-5L was found. HRQL assessed by the K-BILD questionnaire did not differ significantly between patients with IPF and those with HP. In contrast, EQ-5D-5L scores were significantly lower in IPF compared to HP, although no significant differences were observed between IPF and fHP. Both questionnaires demonstrated significant differences in HRQL between fHP and nfHP, while no differences were found between fHP patients with and without UIP pattern. Additionally, HRQL measured by K-BILD was associated with gender-age-physiology (GAP) stage in both IPF and HP cohorts. HRQL according to the K-BILD was mainly associated with cough severity (LCQ), 6-minute walk distance (6MWD), dyspnea intensity (mMRC) and lung function parameters [forced vital capacity (FVC)]. For the EQ-5D-5L, the main predictors of lower HRQL were reduced exercise capacity (6MWD) and higher cough burden (LCQ). According to the results of ROC analysis, the predictors of HRQL score less than 50 points (K-BILD): cough score <13 points (LCQ) and dyspnea score of ≥3 (mMRC). Conclusions: Patients with fHP, especially with UIP pattern, exhibit similar clinical features and functional decline as seen in IPF patients. Cough severity, dyspnea, and exercise capacity were the strongest predictors of reduced HRQL, highlighting the need for comprehensive symptom assessment and individualized management in both IPF and HP. K-BILD and EQ-5D-5L are reliable tools for assessing HRQL and identifying significant clinical and functional factors.